Bamco Inc. NY Sells 11,174 Shares of argenx SE (NASDAQ:ARGX)

Bamco Inc. NY cut its position in argenx SE (NASDAQ:ARGX) by 4.3% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 250,304 shares of the company’s stock after selling 11,174 shares during the quarter. Bamco Inc. NY’s holdings in argenx were worth $135,685,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the company. Erste Asset Management GmbH purchased a new stake in shares of argenx in the third quarter worth $9,007,000. Captrust Financial Advisors bought a new position in argenx in the 3rd quarter worth about $243,000. Hantz Financial Services Inc. increased its stake in argenx by 8.9% in the 3rd quarter. Hantz Financial Services Inc. now owns 528 shares of the company’s stock worth $286,000 after acquiring an additional 43 shares during the last quarter. Alkeon Capital Management LLC raised its holdings in shares of argenx by 15.0% in the 3rd quarter. Alkeon Capital Management LLC now owns 345,000 shares of the company’s stock valued at $187,018,000 after acquiring an additional 45,000 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of argenx by 4,344.2% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 40,842 shares of the company’s stock valued at $22,140,000 after acquiring an additional 39,923 shares during the last quarter. 60.32% of the stock is owned by institutional investors.

argenx Stock Performance

NASDAQ:ARGX opened at $616.55 on Monday. argenx SE has a fifty-two week low of $327.73 and a fifty-two week high of $620.28. The firm has a market cap of $37.22 billion, a PE ratio of -700.63 and a beta of 0.61. The business has a 50 day moving average price of $565.73 and a 200-day moving average price of $497.22.

argenx (NASDAQ:ARGX) last posted its quarterly earnings results on Thursday, October 31st. The company reported $1.39 EPS for the quarter, beating analysts’ consensus estimates of $0.10 by $1.29. The company had revenue of $588.88 million during the quarter, compared to analyst estimates of $543.29 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. During the same period in the prior year, the business posted ($1.25) EPS. Research analysts predict that argenx SE will post 2.2 EPS for the current year.

Analyst Ratings Changes

ARGX has been the topic of several research analyst reports. Wolfe Research upgraded shares of argenx from a “peer perform” rating to an “outperform” rating and set a $697.00 price objective on the stock in a research report on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft lowered shares of argenx from a “buy” rating to a “hold” rating in a report on Friday, October 4th. HC Wainwright reaffirmed a “buy” rating and set a $617.00 price objective on shares of argenx in a report on Wednesday, November 20th. Raymond James reiterated a “strong-buy” rating and issued a $605.00 target price on shares of argenx in a research report on Thursday, October 10th. Finally, Evercore ISI raised their price target on argenx from $675.00 to $706.00 and gave the company an “outperform” rating in a research report on Thursday, November 21st. Three research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, argenx has an average rating of “Moderate Buy” and an average target price of $630.42.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.